| Jun 18 |
UroGen Pharma stock slumps after pricing stock and warrants offering
|
| Jun 18 |
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
|
| Jun 17 |
UroGen Pharma commences public offering of ordinary shares
|
| Jun 17 |
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
|
| Jun 17 |
UroGen: Q3 NDA Opens Hefty Revenue Opportunity
|
| Jun 17 |
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
|
| Jun 13 |
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
|
| Jun 13 |
UroGen surges on updated late-stage data for bladder cancer therapy
|
| Jun 13 |
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
|
| Jun 6 |
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
|
